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ABSTRACT 
Objective: The aim of this study was to improve the aqueous solubility of a poorly water soluble drug griseofulvin. 
Methods: To accomplish this goal a technique of solid dispersion with polyvinyl pyrolidone (k30) and poloxamer 407 was used. Solubility of 
griseofulvin alone and the solid dispersion were performed in 10 ml purified water and measured spectrophotometrically at λ Rmax R295 nm to detect 
the coefficient of improvement.  
Results: Solubility of griseofulvin alone was found to be 0.812 mg and the solubility of solid dispersion ranged from1.64 to 9.56 mg. After 
generating polynomial models correlating the variables using a D-Optimal mixture design, an optimal formulation with desired response was 
proposed by the statistical package. For validation, a new solid dispersion formulation based on the optimized composition was prepared and tested 
for solubility of griseofulvin. The optimized solid dispersion formulation enhances the solubility of griseofulvin by about 12 folds. Increase the 
amount of poloxamer in the optimized formulation increases the griseofulvin solubility to about 6 folds more than the optimized form. 
Conclusion: solid dispersion technique in conjunction with statistical design was shown to be very efficient for the optimization and improvement 
of aqueous solubility of poorly soluble drugs. 
Keywords: Solid dispersion, Griseofulvin solubility, Optimization.  
 
INTRODUCTION 
Oral dosage forms could be considered as the most convenient way 
to deliver the drug to patients. However, many problems must be 
solved before formulating the drug as an oral dosage form. One of 
these problems is the solubility of the drug. A lot of poorly water 
soluble drugs have been developed in the pharmaceutical field. 
Therefore, increasing water solubility to increase bioavailability of 
these drugs is a great challenge that facing the pharmaceutical 
researchers. Many techniques have been developed to enhance drug 
water solubility such as salt formation [1], simple grinding [2], 
grinding with additives [3], inclusion the drug with cyclodextrin [4], 
or solid dispersion. 
Solid dispersion could be defined as the dispersion of the active drug 
in an inert matrix and was first introduced by Sekiguchi and Obi [5]. 
Many trials to prepare solid dispersion containing the desired drug 
as solvent emulsion evaporation [6,7], hot melting [8,9], solvent 
evaporation [10], spray drying[11, 12] and supercritical 
fluid[13]have been reported in the literature to improve aqueous 
solubility of poorly water soluble drugs and consequently their 
bioavailability. As more researchers are attracted to spend much 
effort concerning solid dispersion techniques, better understanding 
of solid dispersion molecular structure associated with its in vitro/in 
vivo performance[14-16] could be achieved and consequently more 
solid dispersion-dosage forms will be introduced to pharmaceutical 
market.  
Griseofulvin is white or yellowish-white, microfine powder, the 
particles of which generally have a maximum dimension of up to 5 
μm, although larger particles that may exceed 30 μm may 
occasionally be present [17]. Griseofulvin is a broad spectrum 
antifungal agent used to treat mycotic disease of the skin, Hair, and 
Nails due to Microsporum, Trichophyton, or Epidermophyton respond 
to the drug therapy. It has a poor water solubility which limits its 
bioavailability and consequently medicinal uses. Many investigations 
were reported to increase its aqueous solubility and therefore 
bioavailability[16, 18, 19]. 
Polyvinylpyrrolidone (PVP), also commonly called Polyvidone or 
Povidone, is a water-soluble polymer made from the monomer N-
vinylpyrrolidone. When dry, PVP is a light flaky powder, which 
readily absorbs up to 40% of its weight in atmospheric water. In 
solution, it has excellent wetting properties and readily forms films. 
PVP is a branched polymer, meaning its structure is more 
complicated than linear polymer, though it lies in a two-dimensional 
plane [20]. 
Poloxamers are nonionic polyoxyethylene–polyoxypropylene 
copolymers used primarily in pharmaceutical formulations as 
emulsifying or solubilizing agents [21]. The polyoxyethylene 
segment is hydrophilic while the polyoxypropylene segment is 
hydrophobic. All of the poloxamers are chemically similar in 
composition, differing only in the relative amounts of propylene and 
ethylene oxides added during manufacture. Their physical and 
surface-active properties vary over a wide range and a number of 
different types are commercially available. Poloxamers are used as 
emulsifying agents in intravenous fat emulsions, and as solubilizing 
and stabilizing agents to maintain the clarity of elixirs and syrups. 
The traditional method of experimental design (one-factor-at-a-
time) has many disadvantages as cost prohibitive, does not provide 
any information about the position of the optima and may call for an 
unnecessarily large number of runs. The application of statistical 
experimental design in  pharmaceutical product development has 
been demonstrated to be an efficient and satisfactory method to 
acquire the necessary information that correlate the independent 
variables, or factors, with the dependent variables, or responses 
relevant to formulation composition, and/or manufacturing 
processing parameters[22-24]. One of the most popular 
experimental design methods is response surface methodology 
(RSM). RSM, such as the D-optimal design, is commonly used to 
reveal the main effects and interaction effects between the 
independent variables of the experiment [25, 26]. 
The objective of this work was to improve the aqueous solubility of a 
poorly water soluble drug (griseofulvin was selected as a model 
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drug). To achieve this objective, i) solid dispersions made from 
different proportions of griseofulvin, polyvinyl pyrolidone, and 
poloxamer as generated from D-optimal experimental design were 
prepared, ii) the dissolution of the different solid dispersions was 
investigated, and iii) optimized solid dispersion that generated from 
the experimental design was prepared and investigated in term of, 
solubility, thermal analysis, X-ray diffraction, and scanning electron 
microscopy (SEM).  
MATERIALS AND METHODS 
Material 
Griseofulvin was obtained from Hawkins Inc., Pharmaceutical group 
(USA). Polyvinylpyrolidone k30 and poloxamer 407were provided 
by Sigma-aldrich (Germany). Absolute ethyl alcohol was purchased 
from HOLYLAND Inc., KSA. Water used in this study was purified by 
water purification system, Direct-Q5, millipore (USA). All chemicals 
were used as supplied without further modification. 
Methods 
Experimental design 
A 14-run, three-factor, two-level D-Optimal mixture design was 
employed in this study to construct polynomial models in the form: 
Y = ARoR + AR1RXR1R + AR2RXR2R + AR3RXR3R + AR4RXR1RXR2R + AR5RXR2RXR3R + AR6RXR1RXR3R + AR7RXR12R + 
AR8RXR2 2R + AR9RXR3 2R + E, where 
AR1R-AR0R are the coefficients of the respective variables and their 
interaction terms, and E is an error term. These models were used to 
describe the effect of three formulation ingredients: griseofulvin 
(XR1R), polyvinylpyrrolidone(XR2R), and poloxamer (XR3R) on the solubility 
of griseofulvin. A summary of the dependent and independent 
variables that were evaluated in this study and the constraints that 
were placed on the response are given in table 1. The range of each 
factor was chosen based on preliminary studies. 
To generate these empirical models, an experimental design was 
created using the Design-Expert software (v.5.07; State-Ease, Inc., 
Minneapolis, MN). In this design (Table 2), 14 different ternary-
blends were suggested based on the constrains and limits given in 
table 1. These design points represented factorial points (high and 
low level from the constraints on each factor), centers of edges 
(points midway between adjacent factorial points), constrains plane 
centroid points, axial check points, and an overall center point. A 
schematic representation of the design is given in fig. 1. 
Preparation of solid dispersions 
Solid dispersions were prepared from different griseofulvin, PVP 
and poloxmer ratios as illustrated in table 1 using solvent method 
[27]. The accurate amount of the drug and poloxamer was dissolved 
in 100 ml ethanol and sonicated for 10 minutes (VWR,Model 75DGM, 
Bristol, CT, USA). The accurate amount of PVP was added to the 
solution and sonicated for another 10 minutes. The sonicated 
solution was evaporated under reduced pressure using Rotavapor 
RII (BUCHI, Germany). Then the drug solid dispersion was kept in 
drying oven(VWR, Model 1350GM, Bristol, CT, USA) at 45 PoPC for 48 
hours. The dried material was ground in a mortar, sieved through a 
#80 sieve and subjected to further evaluation. 
 
Table 1: Independent and dependent variables of the D-Optimal mixture design (3-factor, 2-level design) 
High level Low level Independent variables 
2.0 0.5 X1 = Griseofulvin amount (g) 
2.0 0.5 X2 = PVP amount (g) 
0.5 0 X3 = Poloxamer amount (g) 
   Constrains on response 
Goal  Upper limit Lower limit  Dependent variable  
Maximum  9.54  1.64 Y = Solubility  
 
 
Fig. 1: Standard error plot and a schematic representation of 
the three-component D-Optimal mixture design with each 
corner of the triangle corresponding to one component. Dots 
represent the location of each design points (the 14 runs of the 
experimental design) within the design space. Dots with a (2) 
indicate that the point was replicated. Numbers in the boxes are 
the predicted variance at design point 
 
Solubility study 
Saturation solubility measurements were assayed through 
ultraviolet absorbance determination at 295 nm using an UV 
spectrophotometer (6800 UV-VIS, JENWAY, UK). An excess amount 
of griseofulvin powder and solid precipitate samples was added to 
10 ml of de ionized water contained in volumetric flasks. The flasks 
were stirred in the shaking water bath (lab Tech, Korea)at 100 rpm 
for 72 hours at a temperature of 25 ± 0.5P0PC.  
Visual inspection was carefully made to ensure that there was an 
excess sample in solid state indicating that saturation had been 
reached. Samples were centrifuged (NF 200, nȕve, Turkey)  for 30 
minutes at 5000 rpm and diluted to determine the solubility of 
griseofulvin from the different samples.  
Differential scanning calorimetry 
Differential scanning calorimetry equipped with a liquid nitrogen 
cooling system (DSC-60, SHIMADZU, Japan)was used to measure the 
thermal behavior of the pure griseofulvin powder, pure polymer and 
the optimized solid precipitates. Samples weighting 2-5 mg were 
heated in hermetically sealed aluminum pans over a temperature 
range of 25-300 P0PC at a constant rate of 30 P0PC / min.  
X-Ray Powder Diffraction (PXRD) 
Samples were analyzed using powder X-ray (XRD- XMD- 300, 
Unisantis, Germany) diffractometer equipped with a Bragg-Brentano 
optical setup. Copper Ka radiation (wavelength 1.5406 A°) was used 
with a long fine focus X-ray tube. The tube voltage and amperage 
were set to 40 kV and 30 mA, respectively. The divergence and 
scattering slits was set at 0.58 and the receiving slit was set at 0.15 
mm. Diffracted radiation was detected by a NaI scintillation detector.  
Samples were scanned at 0.02 2θ/s from 5 to 40P0P2 θ. Scans of each 
sample were run in triplicate. All powder samples were front filled 
using a circular area aluminum holder. A silicon standard was 
analyzed to check the instrument alignment each time before sample 
measurements. 
Scanning electron microscopy 
Powder samples were analyzed by scanning electron microscope 
(SEM). The particles were deposited on double-sided carbon tap 
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(diameter 12 mm, Oxon, Oxford Instruments, UK). A SEM (InspectTM
The probability value (α) for determination of statistical significance 
was set at 0.05, which indicates thata “hypothesis” theory would be 
rejected if the calculated p-value was less than 0.05 in favor of an 
alternative theory. The first step toward an optimal statistical 
analysis was to select the model that best (1) describes and (2) fits 
the data. Therefore, results were analyzed by the sequential model 
comparison test. Results of the sequential model comparison, which 
indicate whether a model could describe a response, are given in 
table 3. As seen from the table, the linear model was statistically 
significant (
 
S50, FEI Company,Czech Republic) operating at 15 KV was used to 
obtain the electron micrograph of the powder samples. 
RESULTS AND DISCUSION 
Experimental design 
A 14-run, three-factor, two-level D-optimal design was utilized in 
this study to correlate the effect of the level of griseofulvin, PVP, and 
poloxamer on the enhancing the aqueous solubility of griseofulvin. 
The independent and dependent variables that were examined in 
this study are listed in table 1. The composition of the 14 runs and 
the response that was investigated in this study, aqueous solubility 
of griseofulvin, are given in table 2. Data generated for the response 
were analyzed using the Design-Expert software.  
*
Statistical significance, however, was not improved by adding either 
quadratic or cubic terms. The lack of fit test was subsequently 
performed to further demonstrate the suitability of a given model. 
Lack-of-fit test, which was calculated based on the residual sum of 
squares, diagnoses whether a model adequately fits the data. As seen 
in table 4, large p values of the linear model (
p < 0.0026), which indicates that the model adequately 
describes the response (solubility of griseofulvin).  
*
Y = 4.576 X
p > 0.0702) for 
griseofulvin solubilityindicates that the linear model adequately fits 
thedata. The linear model that describe griseofulvin solubility will be 
in the following form:  
1 + 0.1041 X2 – 0.530 X3
Where Y represents griseofulvin solubility, X
. 
1, X2, and X3
A more elaborate discussion of the effect of study factors is given in 
the following sections. 
 represent 
the amount of griseofulvin, PVP and poloxamer respectively. 
 
Table 2: Composition of the three-component blend in each of the 14-runs of the D-Optimal mixture design 




A: Griseofulvin (gm) Run 
 9.36 0.00 1.25 1.25 1 
 8.64 0.00 0.50 2.00 2 
 2.46 0.25 1.75 0.50 3 
 3.35 0.50 1.50 0.50 4 
 2.00 0.00 2.00 0.50 5 
 9.56 0.00 0.50 2.00 6 
 6.56 0.50 0.50 1.50 7 
 8.56 0.13 0.81 1.56 8 
 2.39 0.50 1.50 0.50 9 
 9.35 0.50 0.50 1.50 10 
 3.07 0.50 1.00 1.00 11 
 1.71 0.25 1.44 0.81 12 
 3.85 0.25 0.50 1.75 13 
 1.64 0.00 2.00 0.50 14 
 
Table 3: Sequential model comparison 
P-Value F value Mean square DF Sum of squares Source 
  375.45 1 375.45 Mean 
0.0026 10.76 45.92 2 91.84 Linear 
0.2620 1.61 5.89 3 17.67 Quadratic 
0.0651 4.77 11.87 1 11.87 Special Cubic 
0.1309 3.45 4.19 3 12.56 Cubic 
  1.21 4 4.84 Residual 
    36.73 14 514.23 Total 
 
Table 4: Lack of fit of different models 
*F value P-Value Mean square DF Sum of squares Source 
0.0702 4.97 6.01 7 42.10 Linear 
0.0730 5.05 6.11 4 24.42 Quadratic 
0.1309 3.46 4.19 3 12.56 Special Cubic 
  0.00 0 0.00 Cubic 
    1.21 4 4.84 Pure error 
 
Effect of study factors on griseofulvin solubility 
The effect of the amounts of griseofulvin (X1), PVP (X2), and 
poloxamer (X3) on the solubility of griseofulvin was investigated by 
measuring the absorbance of the dissolved griseofulvin at λ max 295 
nm. A contour plots showing the effect of X1, X2 and X3 on the 
solubility of griseofulvin is given in fig. 2. As seen from the figure, an 
increase in the amount of X1 and X2 led to an increase in the 
solubility of griseofulvin. On the other hand, increase the amount of 
X3
Therefore increasing the amount of PVP in the solid dispersion 
increased the surface area of griseofulvin dispersed on the surface of 
PVP. On dissolution, PVP takes water and increased the wetting of  resulted in a decrease in griseofulvin solubility. These findings 
could be explained on the basis of the surface area and wetting of the 
drug. Increasing the amount of griseofulvin, increased the total 
surface area of the drug and consequently increased the amount of 
drug available for dissolution. PVP is a two-dimensional plane 
polymer [20], which is highly water soluble without exerting 
swelling properties.  
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griseofulvin and consequently increase solubility of griseofulvin. On 
the other hand, poloxamer had a negative impact on griseofulvin 
solubility as it appears from the negative sign of poloxamer 
coefficient (- 0.530) in the linear model. Increasing the amount of 
poloxamer, decreased the solubility of griseofulvin. This finding 
could be explained depending on the amounts of poloxamer. The 
amount of poloxamer used (up to 0.5 gm) may be lower than the 
concentration required to produce micelles which could enhance the 
solubility of griseofulvin. 
 
Fig. 2: Contour plot showing the effect of solid dispersion 
composition and the level of griseofulvin, PVP, and poloxamer 
on the solubility of riseofulvin 
 
Numbers in the boxes are the estimated solubility in milligrams 
Optimization of solid dispersion formulation  
After generating the linear equation relating the dependent and 
independent variables, the amount of each ingredient (X1 − X3
Differential scanning calorimetry (DSC)  
) was 
optimized to yield a high griseofulvin solubility. Based on the linear 
model and constraint, an optimal solid dispersion formulation was 
suggested by the statistical package. The suggested solid dispersion 
composition was a binary blend of griseofulvin (2 gm), PVP (0.5 gm), 
and no poloxamer with a maximum predicted solubility of 9.204 mg 
of griseofulvin. To validate the optimization process, a new solid 
dispersion was prepared based on the proposed composition and 
tested for dissolution. Solubility of the optimized formulation was 
found to be 9.870 mg compared to 0.812mg of griseofulvin alone 
under the same condition.  
Studying the behavior of the substances during heating was 
performed using DSC to detect if there is any complex formation 
between griseofulvin and PVP or if there is any change in the crystal 
structure of griseofulvin in the optimized solid dispersion 
formulation.  
 
Fig. 3: Thermogram of, griseofulvin, PVP, and optimized 
formulation 
 
Thermogram of griseofulvin, PVP, and optimized formulation is 
illustrated in fig. 3. A sharp peak at 223.7oC representing the melting 
point of griseofulvin, while PVP shows a broad peak starts at about 
45 0C and ends at 120 0
X-ray powder diffraction (XRPD) 
C representing the evaporation of the 
moisture and melting of PVP[27]. The presence of the peaks of 
griseofulvin and PVP in the thermogram of the optimized solid 
dispersion formulation means that there is no possibility of complex 
formation between griseofulvin and PVP. 
Presence of the substance as either crystalline or amorphous form 
could be detected by performing X-ray powder diffraction test. 
There is only one crystalline form for griseofulvin reported in the 
literature [28]. Fig. 4 shows the PXRD pattern of the griseofulvin, 
PVP and the optimized solid dispersion formulation.  
Data were shown in the fig. indicate that the griseofulvin in the 
optimized formulation corresponds to the pure crystalline form and 
there is no change in the peaks intensities which means that 
griseofulvin present as a crystalline form and not changed to 
amorphous form. This finding was in close agreement with what was 
reported in the literature that drug in solid dispersion could be 
dispersed as crystalline particles [29]. 
 
Fig. 4: XRPD of griseofulvin, PVP, and optimized solid dispersion 
formulation 
 
Scanning electron microscopy 
Scanning electron microscope was used to detect the morphological 
difference between the optimized form and the pure griseofulvin 
powder. As showed in fig. 5, pure griseofulvin presents as a clumps 
because of the high lipid solubility of the drug. On the other hand, 
griseofulvin in the optimized form presents as a crystalline particles 
that are separated by the carrier PVP. Consequently, griseofulvin in 
the optimized form will have a high water solubility (9.870 mg) than 
griseofulvin alone (0.812 mg) because of the high surface area. 
 
 
Fig. 5: SEM photos of (a) Pure griseofulvin and (b) optimized 
griseofulvin formulation 
 
Effect of increasing amount of poloxamer on griseofulvin 
solubility 
Effect of incorporating high amounts of poloxamer 409 on the 
aqueous solubility of griseofulvin was investigated. Poloxamer was 
added to the optimized form during preparation of the solid 
dispersion in a ratio ranged from 0.5: 1, 1: 1, and 2: 1 of poloxamer 
to optimized form respectively. Total amount of griseofulvin 
dissolved from the resulting solid dispersion was measured 
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spectrophotometrically. Incorporating high amount of poloxamer 
resulted in increasing the aqueous solubility of griseofulvin than the 
optimized form. The amount of dissolved griseofulvin was 57.17, 50.38, 
and 36.15 mg for 0.5: 1, 1: 1, and 2: 1 respectively. High amount of 
griseofulvin dissolved was obtained from solid dispersion prepared from 
0.5: 1 poloxamer to optimized form. This finding could be attributed to 
the ability of poloxamer to produce micelles which will enclose 
griseofulvin and consequently increasing its aqueous solubility. 
Increasing poloxamer amount to 1: 1 and 2: 1 of the optimized form 
resulting in decreasing the solubility of griseofulvin which could be 
explained on the basis of micelles aggregation. At high amount of 
poloxamer, produced micelles will aggregate to each other without 
enclosing more amounts of griseofulvin resulting in the observed 
decrease of griseofulvin amount dissolved. 
CONCLUSION 
Solid dispersion prepared from poorly aqueous soluble drug with a 
polymer that has high water solubility and surface area could be a 
useful technique to improve the aqueous solubility of the drug to 
about 12 folds. In this study for example, a D-optimal design was 
proven efficient in optimizing griseofulvin solid dispersion made of a 
ternary blend of griseofulvin, PVP, and poloxamer. While high 
concentrations of griseofulvin in the solid dispersion were deemed 
essential for solubility improvement, addition of PVP was found to 
enhance griseofulvin aqueous solubility. Poloxamer amount was 
found to have a versatile effect on griseofulvin solubility. At small 
amounts, poloxamer was found to be inefficient in enhancing 
griseofulvin solubility. On the other hand, high amounts of 
poloxamer to optimized formulation (0.5: 1) increased griseofulvin 
solubility to about 6 folds than the optimized formulation, while 
further increase of poloxamer amounts decreased griseofulvin 
aqueous solubility. 
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